Evidence map›Paper›PMID 35217535›Full record

ArticleBMJ open2022

Australian Parkinson's Genetics Study (APGS): pilot (n=1532).

Svetlana Bivol, George D Mellick, Jacob Gratten, Richard Parker, Aoibhe Mulcahy, Philip E Mosley, Peter C Poortvliet, Adrian I Campos, Brittany L Mitchell, Luis M Garcia-Marin and 9 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

Svetlana BivolQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0002-7085-8366
George D MellickGriffith Institute for Drug Discovery (GRIDD), Griffith University, Brisbane, QLD, Australia.ORCID 0000-0002-7211-4651
Jacob GrattenMater Research, Translational Research Institute, Brisbane, QLD, Australia.ORCID 0000-0003-1293-409X
Richard ParkerQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0003-1451-5622
Aoibhe MulcahyQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Philip E MosleyQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0003-1721-3419
Peter C PoortvlietGriffith Institute for Drug Discovery (GRIDD), Griffith University, Brisbane, QLD, Australia.ORCID 0000-0002-5562-4254
Adrian I CamposQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0003-3468-8619
Brittany L MitchellQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0002-9050-1516
Luis M Garcia-MarinQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0003-4731-6558
Simone CrossQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Mary FergusonQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Penelope A LindQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0002-3887-2598
Danuta Z LoeschSchool of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia.
Peter M VisscherInstitute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0002-2143-8760
Sarah E MedlandQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0003-1382-380X
Clemens R ScherzerCenter for Advanced Parkinson Research, Harvard Medical School and Brigham & Women's Hospital, Boston, MA, USA.ORCID 0000-0002-0567-9193
Nicholas G MartinQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia miguel.renteria@qimrberghofer.edu.au Nick.Martin@qimr.edu.au.ORCID 0000-0003-4069-8020
Miguel E RenteríaQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia miguel.renteria@qimrberghofer.edu.au Nick.Martin@qimr.edu.au.ORCID 0000-0003-4626-7248
QIMR Berghofer Medical Research Institute · AUThe University of Queensland · AUQueensland University of Technology · AUBrigham and Women's Hospital · USGriffith University · AULa Trobe University · AUTranslational Research Institute · AU

Funding

GENOTYPE/PHENOTYPE RELATIONSHIPS IN FRAGILE X FAMILIESR01HD036071 · NICHD · UNIVERSITY OF CALIFORNIA DAVIS · PI PAUL J HAGERMAN, RANDI J. HAGERMAN · 1998 to 2026
$13.8M
NICHD NIH HHS R01 HD036071
6 · The paper itself

Abstract

purposeParkinson's disease (PD) is a neurodegenerative disorder associated with progressive disability. While the precise aetiology is unknown, there is evidence of significant genetic and environmental influences on individual risk. The Australian Parkinson's Genetics Study seeks to study genetic and patient-reported data from a large cohort of individuals with PD in Australia to understand the sociodemographic, genetic and environmental basis of PD susceptibility, symptoms and progression.

participantsIn the pilot phase reported here, 1819 participants were recruited through assisted mailouts facilitated by Services Australia based on having three or more prescriptions for anti-PD medications in their Pharmaceutical Benefits Scheme records. The average age at the time of the questionnaire was 64±6 years. We collected patient-reported information and sociodemographic variables via an online (93% of the cohort) or paper-based (7%) questionnaire. One thousand five hundred and thirty-two participants (84.2%) met all inclusion criteria, and 1499 provided a DNA sample via traditional post. FINDINGS TO DATE: 65% of participants were men, and 92% identified as being of European descent. A previous traumatic brain injury was reported by 16% of participants and was correlated with a younger age of symptom onset. At the time of the questionnaire, constipation (36% of participants), depression (34%), anxiety (17%), melanoma (16%) and diabetes (10%) were the most reported comorbid conditions. FUTURE PLANS: We plan to recruit sex-matched and age-matched unaffected controls, genotype all participants and collect non-motor symptoms and cognitive function data. Future work will explore the role of genetic and environmental factors in the aetiology of PD susceptibility, onset, symptoms, and progression, including as part of international PD research consortia.

Indexed as

Parkinson DiseaseAnxietyAustraliaConstipationHumansMaleSurveys and QuestionnairesepidemiologygeneticsneurologyParkinson’s disease

Identifiers

PMID35217535
PMCPMC8883215
OpenAlexW4214619434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.